Philips showcases AI-enabled integrated solutions at #ESCCongress to deliver better cardiac care to more people

Amsterdam the Netherlands – At the European Society of Cardiology 2024 Congress, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will demonstrate how the company is uniquely positioned to integrate imaging, devices, software and informatics to provide timely and precise information for addressing diagnostic and interventional cardiology, bringing better cardiac care to more people.

In the Philips Future Health Index (FHI) 2024 Global Report – the largest global survey of its kind, featuring insights from nearly 3,000 healthcare leaders across 14 countries – 75% of cardiology leaders report that staff shortages are negatively impacting patient care within their organizations. Adding to the challenge is the global shortage of healthcare professionals. To address these challenges, cardiology leaders are increasingly turning to AI (artificial intelligence), remote patient monitoring, virtual care, and automation as viable solutions.

“With the growing volume and complexity of patient cases and pressures to improve departmental efficiency, the demands on cardiology departments have never been higher. As the 2024 FHI data shows, cardiology leaders are quickly realizing the potential of AI, with 40% saying their organizations plan to invest in generative AI in the next 12 months,” said Dr. Atul Gupta, Chief Medical Officer of Diagnosis and Treatment at Philips. “By leveraging AI across our advanced technology portfolios in Diagnosis & Treatment, Enterprise Informatics, and Patient Monitoring, our integrated solutions can help solve cardiology’s daily challenges.”

AI at the forefront of structural heart disease diagnosis and treatment

At ESC 2024, Philips will spotlight the next dimension in echocardiography leveraging first-to-market AI-based capabilities that help accelerate and automate diagnosis of echocardiography measurements. This advanced platform features innovative AI tools designed to support the diagnosis of structural heart disease (SHD), including a new automated 3D tricuspid valve quantification tool [1], and new 3D color flow quantification to assist in diagnosing mitral regurgitation. Also featured is Philips’ real-time 3D Intracardiac Echocardiography (ICE) Catheter – VeriSight Pro – designed to give physicians more confidence and control during a variety of minimally invasive procedures in SHD and electrophysiology. Additionally, Philips EchoNavigator, integrated with the Philips Azurion Image-Guided Therapy System, assists heart teams in treating complex SHD conditions, such as heart valve repair or replacement with increased ease and efficiency.

Putting heart into cancer survivorship with new AI apps to address cardiotoxicity

While current cancer treatments such as radiation therapy and chemotherapy may improve recovery outcomes for patients and keep negative side effects to a minimum, they can also carry an increased risk of heart disease. Studies show that adult survivors of breast, prostate, lung, colorectal, hematopoietic and lymphatic cancers face a 37% higher risk of developing cardiovascular disease (CVD), with nearly half ultimately succumbing to it [2][3]. Survivors of the most common childhood cancers also face an excess risk of late mortality compared to the general population [4].

Next generation cardiovascular ultrasound enhanced with cardiology informatics

Making its debut at ESC 2024 is Philips’ latest AI-enabled cardiovascular ultrasound platform featuring industry-first applications designed to accelerate cardiac ultrasound analysis with proven technology. Now integrated with Philips Ultrasound Workspace, this platform enables the same, supporting consistent diagnostic capabilities on and off-cart, allowing for advanced analysis of vendor-agnostic data to enhance confident decision-making throughout the cardiology care path. Launched earlier this year and also making its debut is Philips’ new mini ultrasound transducer X11 4t, fully compatible with the company’s EPIQ CVx ultrasound system. As one of the most versatile mini-TEE transducers in the industry, it expands access to care for more patients, including the smallest undergoing complex intracardiac procedures like valve repairs.

Cardiac MR and CT drive increased productivity to help improve patient care

Philips AI-enabled Spectral CT 7500 offers advanced cardiac imaging with low-dose technology and a reduction in time to diagnosis [5]. Additionally, Philips CT 5300 features cutting-edge AI applications to increase productivity in diagnosis, interventional procedures, and screening, and meets the advanced diagnostic imaging requirements for cardiac care patient guidelines.